Conformal Medical

Conformal Medical: Innovating stroke prevention devices for non-valvular atrial fibrillation patients since 2016.

: 33
: Acquired, subsidiary of W. L. Gore & Associates
: 2016
: Nashua, NH, USUnited States

Library

conformalmedical.comCrawled Oct 15, 2026

Product

3 pages

Claas/company/claas
CLAAS System/company/claas-system
Clinical Need/company/clinical-need
Conformal is a privately held medical device company that designed the CLAAS System to seal the LAA and reduce the risk of stroke.

Blog

1 page

Study Demonstrates Successful Device Size Selection When…/company/news/study-demonstrates-successful-device-size-selection-when-assessing-left-atrial-appendage-by-angiography-compared-to-tee

Press

1 page

Conformal Medical’s CLAAS System Demonstrates Low…/company/news/conformal-medicals-claas-system-demonstrates-low-thrombogenicity-compared-to-commercially-available-laao-devices

Careers & Hiring

1 page

Apply/company/apply

About

1 page

About/company/about

Contact

1 page

Contact/company/contact

Homepage

1 page

Homepage/
Conformal is a privately held medical device company that designed the CLAAS System to seal the LAA and reduce stroke risk.

Coverage

6 items

W. L. Gore & Associates Completes Acquisition of Conformal Medicalconformalmedical.com/company/news/w-l-gore-associates-completes-acquisition-of-conformal-medical
W. L. Gore & Associates acquires Conformal Medical, developer of the **CLAAS® AcuFORM™ System**, an investigational left atrial appendage occlusion (LAAO) device. The deal expands Gore’s portfolio in **endovascular treatments**, reinforcing its focus on next-generation cardiovascular solutions. Gore announced the acquisition in January 2026, finalizing it in February.
Feb 2026Conformal MedicalNews article
Conformal Medical Closes $32 Million Series D Extension to Advance its Next-Generation Left Atrial Appendage Occlusion Technologyprnewswire.com/news-releases/conformal-medical-closes-32-million-series-d-extension-to-advance-its-next-generation-left-atrial-appendage-occlusion-technology-302528045.html
Conformal Medical secures a $32 million Series D extension to develop its next-generation left atrial appendage occlusion (LAAO) technology. The company focuses on improving treatment for atrial fibrillation by reducing stroke risk through innovative device solutions. Funding will support further clinical and engineering advancements in its proprietary occlusion platform.
Aug 2025PR NewswireNews article
The Conformal Medical CLAAS® AcuFORM™ Left Atrial Appendage Occlusion (LAAO) System to be Prominently Featured at TCT 2024prnewswire.com/news-releases/the-conformal-medical-claas-acuform-left-atrial-appendage-occlusion-laao-system-to-be-prominently-featured-at-tct-2024-302283714.html
Conformal Medical highlights its next-generation **CLAAS® AcuFORM™ Left Atrial Appendage Occlusion (LAAO) System** at **TCT 2024**, a leading cardiovascular conference. The system represents an advanced solution for stroke risk reduction in patients with atrial fibrillation. The company emphasizes its innovative design and potential clinical impact in structural heart interventions.
Oct 2024PR NewswireNews article
Conformal Medical Announces Compelling One-Year Data from its Left Atrial Appendage Occlusion (LAAO) Early Feasibility Studyprnewswire.com/news-releases/conformal-medical-announces-compelling-one-year-data-from-its-left-atrial-appendage-occlusion-laao-early-feasibility-study-301966208.html
Conformal Medical reports strong one-year outcomes from its **Left Atrial Appendage Occlusion (LAAO)** early feasibility study. The study evaluates the company’s device for stroke risk reduction in patients with atrial fibrillation. Early results demonstrate sustained safety and efficacy after one year of follow-up, supporting further clinical development.
Oct 2023PR NewswireNews article